Emergent Q2 2026 earnings: MCM growth contrasts with NARCAN impairment

Emergent BioSolutions (NYSE: EBS) reported Q2 2026 revenue of $234.3 million, up 66% from $140.9 million, while its diluted GAAP loss widened to $3.49 per share from $0.22. Medical countermeasure deliveries lifted gross margin and adjusted earnings, but a $191.3 million non-cash impairment of the NARCAN asset group drove a $180.2 million GAAP net loss. The company also lowered its full-year outlook and initiated a restructuring plan.

Core financial results

Revenue growth was concentrated in MCM products, where higher smallpox and botulism-related deliveries produced a more favorable product mix and improved fixed-cost absorption. That lifted GAAP gross margin to 50% and adjusted gross margin to 58%, compared with 36% and 49%, respectively, a year earlier.

The operating loss nevertheless reached $125.1 million because total operating expenses included the NARCAN impairment. Excluding specified items, adjusted net income and adjusted EBITDA both increased substantially.

Gross margin percentages use product and services sales, net, as the denominator under the company’s definition. Adjusted figures are non-GAAP measures; 2025 figures were recast to exclude stock-based compensation from these calculations.

Business and segment performance

The quarter showed a pronounced split between MCM Products and Commercial Products. MCM revenue nearly tripled as U.S. government and international deliveries increased, while naloxone revenue declined because of an unfavorable OTC NARCAN price-volume mix in U.S. public-interest channels.

Smallpox MCM growth reflected higher U.S. government ACAM2000 sales, a better CNJ-016 price and volume mix, and higher international TEMBEXA sales. Other Products benefited from the timing of U.S. government and international BAT deliveries. Anthrax MCM grew modestly as a more favorable BioThrax pricing mix offset the absence of international ANTHRASIL sales.

Commercial Products gross margin fell to $6.7 million from $21.7 million, and its margin contracted to 13% from 32%. Cost of sales was nearly unchanged despite the revenue decline because higher KLOXXADO and Canadian branded NARCAN costs offset lower U.S. OTC NARCAN volume.

MCM Products gross margin rose to $107.4 million from $25.8 million, with margin expanding to 64% from 44%. Favorable product mix and higher volumes improved fixed-cost absorption, partly offset by a significant non-recurring manufacturing cost associated with CYFENDUS production.

MCM contract timing lifted Q2, while naloxone reset the outlook

Emergent’s 66% revenue increase did not reflect uniform growth across the portfolio. The largest gains came from MCM deliveries whose timing depends on government purchase options, procurement decisions, funding availability and the company’s ability to complete deliveries. This concentration helped produce a 41% adjusted EBITDA margin in Q2 but also makes quarterly comparisons sensitive to contract timing.

Naloxone moved in the opposite direction. Revenue declined, commercial gross margin contracted by 19 percentage points, and the company recorded the NARCAN asset-group impairment. CEO Joe Papa described the company as being at a critical point in its turnaround, primarily because of the naloxone business.

Emergent is responding by eliminating approximately 90 roles and reorganizing its operations. Management expects about $40 million in annualized savings once the plan is fully implemented. It is also combining R&D, business development and strategy into a new Growth organization.

Profitability, cash flow and balance sheet

The difference between GAAP and adjusted profitability was unusually large. Emergent reported a $180.2 million net loss but $30.9 million of adjusted net income, with $211.1 million of total adjustments. The $191.3 million non-cash impairment was the largest item, while the quarter also included a $20.5 million loss on debt extinguishment, a $10.7 million loss on assets held for sale and $18.8 million of non-cash amortization charges.

Operating cash flow was disclosed on a six-month rather than quarterly basis. For the first half of 2026, operating cash flow was $22.3 million, down from $95.2 million a year earlier. The non-cash impairment and a $39.8 million inventory reduction supported cash flow, while a $107.7 million increase in accounts receivable was a substantial use of cash.

Cash and cash equivalents declined to $139.7 million at June 30 from $205.4 million at the end of 2025. Debt increased to $581.8 million from $572.1 million. During the period, Emergent refinanced its term loan with a new $150 million facility and amended its asset-backed loan facility.

Guidance

Emergent reduced every major full-year forecast provided in the release. The wider GAAP loss incorporates the impairment, but the lower adjusted earnings, adjusted EBITDA and adjusted gross margin ranges show that the outlook revision extends beyond that non-cash charge.

For Q3 2026, the company forecasts revenue of $110 million to $130 million. Full-year assumptions include approximately $40 million of interest expense, capital expenditures of about $17 million and R&D spending equal to roughly 6% of revenue.

Risks investors should monitor

• Government procurement timing: Q2 growth depended heavily on MCM deliveries. Changes in purchase-option timing, government funding or delivery schedules can create substantial quarterly revenue volatility.
• Naloxone pricing and volume: The unfavorable U.S. OTC NARCAN mix reduced both Commercial Products revenue and gross margin, while the impairment indicates a weaker valuation for the associated asset group.
• Execution against reduced guidance: Lower forecasts for revenue, adjusted earnings and adjusted gross margin increase the importance of delivery execution and cost control during the second half.
• Restructuring execution: The planned annualized savings depend on successful implementation of the organizational changes, including the reduction of approximately 90 roles.
• Cash generation and leverage: First-half operating cash flow declined, cash balances fell and debt remained above $580 million, making working-capital management and compliance with financing obligations important.

Summary

Emergent’s Q2 2026 operating performance was driven by favorable MCM delivery timing and mix, which improved gross margin and adjusted profitability. That improvement was offset at the GAAP level by the NARCAN impairment and accompanied by weaker naloxone economics, a lower full-year outlook and a new cost-reduction program. The main issues to follow are the timing and durability of government MCM revenue, stabilization of the naloxone business, restructuring savings and cash generation during the remainder of 2026.